StrataStem Ltd is a spinout biotechnology company seeking to transform the diagnosis and treatment of Alzheimer’s disease

StrataStem is developing innovative drug screening platforms to identify appropriate therapeutics for Alzheimer’s disease (AD). Utilising AD patient derived neural cell models the company is investigating the molecular processes that drive the disease and applying these findings to detect, stratify and to develop interventions that can halt its progression.

The company is using its ground-breaking drug screening platform to model AD and other difficult to treat neurological conditions. They work with industrial pharmaceutical companies to test therapeutics, as well as identify patient cohorts and use their novel modelling technology to identify new disease biomarkers.

StrataStem’s technology will transform the treatment for patients who currently have difficult to treat neurological diseases.

For more information, please contact:

Clare Arkwright
+44 (0)161 603 7760 (office)*
+44 (0)7825 721 202 (mobile)

*As a result of lockdown related to Covid-19, office landline numbers are not currently being monitored. Therefore, please email or phone an alternative number, where possible.